Resumen
La Leucoencefalopatía Multifocal Progresiva (LMP) es una condición grave secundaria a la infección por virus John Cunningham (VJC) derivada de la deficiencia de inmunidad celular innata o adquirida. Se presenta el primer caso reportado en Latinoamérica de (LMP) asociada a Natalizumab (NZB) en un paciente con diagnóstico de esclerosis múltiple recaída-remisión, quien ingresa a urgencias con cuadro clínico de deterioro cognoscitivo, comportamental, motor y de lenguaje de curso progresivo. Se realizaron neuroimágenes con resonancia magnética cerebral sugestivas de LMP, estudios de reacción en cadena de polimerasa en líquido cefalorraquídeo para virus JC, que resultaron negativos en dos oportunidades; el diagnóstico se confirmó mediante la técnica de hibridación in situ en biopsia cerebral. Se realiza este reporte con el fin de resaltar la importancia de la vigilancia clínica y paraclínica en los pacientes con esclerosis múltiple que reciben NZB.
Citas
BAG AK, CURÉ JK, CHAPMAN PR, ROBERSON GH, SHAH R. JC Virus Infection of the Brain. AJNR Am J Neuroradiol. 2010;31(9):1564-76.
JR AJA. Progressive Multifocal Leukoencephalopathy. Continuum Lifelong Learning Neurol. 2012;18(6):1374–1391.
BLOOMGREN G, RICHMAN S, HOTERMANS C, SUBRAMANYAM M, GOELZ S, NATARAJAN A, ET AL. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-80.
GIOVANNONI G. TYSABRI (natalizumab) Benefit/Risk Update & PML Risk Stratification. Biogen indec medical affairs and TYSABRI symmary of product characteristics 2013.
SAFAK M, KHALILI K. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol. 2003;9 Suppl 1:3-9.
BOZIC C RS, PLAVINA T. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70(5):742Y750.
WEBER T, WEBER F, PETRY H, LÜKE W. Immune response in progressive multifocal leukoencephalopathy: an overview. J Neurovirol. 2001;7(4):311-7.
AKSAMIT AJ. Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Microsc Res Tech. 1995;32(4):302-11.
KLEINSCHMIDT-DEMASTERS BK, TYLER KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-74.
POLMAN CH, O’CONNOR PW, HAVRDOVA E, HUTCHINSON M, KAPPOS L, MILLER DH, ET AL. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
BALDWIN KJ, HOGG JP. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol. 2013;26(3):318-23.
DONG-SI T RS, GANGADHARAN A, RICHERT N, DATTA S, MCININCH J, PHILIP J, BOZIC C, BLOOMGREN G BIOGEN IDEC INC. Disability after natalizumab-associated PML in a large cohort of survivors. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosi, Lyon FranceOctober 10–13 2012.
BERGER JR, HOUFF SA, MAJOR EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009;1(6):583-9.
CARSON KR, EVENS AM, RICHEY EA, HABERMANN TM, FOCOSI D, SEYMOUR JF, ET AL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-40.
VERMERSCH P, KAPPOS L, GOLD R, FOLEY JF, OLSSON T, CADAVID D, ET AL. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76(20):1697-704.
KHATRI BO, MAN S, GIOVANNONI G, KOO AP, LEE JC, TUCKY B, ET AL. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-9.
FOX R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med. 2011;78 Suppl 2:S33-7.
O’HARA BA, ATWOOD WJ. Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus. Virus Res. 2008;132(1-2):97-103.
PROCOP GW, BECK RC, PETTAY JD, KOHN DJ, TUOHY MJ, YEN-LIEBERMAN B, ET AL. JC virus chromogenic in situ hybridization in brain biopsies from patients with and without PML. Diagn Mol Pathol. 2006;15(2):70-3.
SAMOREI IW, SCHMID M, PAWLITA M, VINTERS HV, DIEBOLD K, MUNDT C, ET AL. High sensitivity detection of JC-virus DNA in postmortem brain tissue by in situ PCR. J Neurovirol. 2000;6(1):61-74.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.